A citation-based method for searching scientific literature

Rachel Ochs-Ross, Ella J Daly, Yun Zhang, Rosanne Lane, Pilar Lim, Randall L Morrison, David Hough, Husseini Manji, Wayne C Drevets, Gerard Sanacora, David C Steffens, Caleb Adler, Rupert McShane, Raphaël Gaillard, Samuel T Wilkinson, Jaskaran B Singh. Am J Geriatr Psychiatry 2020
Times Cited: 92







List of co-cited articles
742 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Vanina Popova, Ella J Daly, Madhukar Trivedi, Kimberly Cooper, Rosanne Lane, Pilar Lim, Christine Mazzucco, David Hough, Michael E Thase, Richard C Shelton,[...]. Am J Psychiatry 2019
198
70

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Maggie Fedgchin, Madhukar Trivedi, Ella J Daly, Rama Melkote, Rosanne Lane, Pilar Lim, Dawn Vitagliano, Pierre Blier, Maurizio Fava, Michael Liebowitz,[...]. Int J Neuropsychopharmacol 2019
137
68

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Ella J Daly, Madhukar H Trivedi, Adam Janik, Honglan Li, Yun Zhang, Xiang Li, Rosanne Lane, Pilar Lim, Anna R Duca, David Hough,[...]. JAMA Psychiatry 2019
160
57

Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Ella J Daly, Jaskaran B Singh, Maggie Fedgchin, Kimberly Cooper, Pilar Lim, Richard C Shelton, Michael E Thase, Andrew Winokur, Luc Van Nueten, Husseini Manji,[...]. JAMA Psychiatry 2018
260
47

Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
Ewa Wajs, Leah Aluisio, Richard Holder, Ella J Daly, Rosanne Lane, Pilar Lim, Joyce E George, Randall L Morrison, Gerard Sanacora, Allan H Young,[...]. J Clin Psychiatry 2020
78
48

Antidepressant effects of ketamine in depressed patients.
R M Berman, A Cappiello, A Anand, D A Oren, G R Heninger, D S Charney, J H Krystal. Biol Psychiatry 2000
39

Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Carla M Canuso, Jaskaran B Singh, Maggie Fedgchin, Larry Alphs, Rosanne Lane, Pilar Lim, Christine Pinter, David Hough, Gerard Sanacora, Husseini Manji,[...]. Am J Psychiatry 2018
198
35

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Carlos A Zarate, Jaskaran B Singh, Paul J Carlson, Nancy E Brutsche, Rezvan Ameli, David A Luckenbaugh, Dennis S Charney, Husseini K Manji. Arch Gen Psychiatry 2006
33

Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
Jaskaran B Singh, Maggie Fedgchin, Ella Daly, Liwen Xi, Caroline Melman, Geert De Bruecker, Andre Tadic, Pascal Sienaert, Frank Wiegand, Husseini Manji,[...]. Biol Psychiatry 2016
205
27

A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
Jaskaran B Singh, Maggie Fedgchin, Ella J Daly, Peter De Boer, Kimberly Cooper, Pilar Lim, Christine Pinter, James W Murrough, Gerard Sanacora, Richard C Shelton,[...]. Am J Psychiatry 2016
257
27

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
James W Murrough, Dan V Iosifescu, Lee C Chang, Rayan K Al Jurdi, Charles E Green, Andrew M Perez, Syed Iqbal, Sarah Pillemer, Alexandra Foulkes, Asim Shah,[...]. Am J Psychiatry 2013
666
25

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
A John Rush, Madhukar H Trivedi, Stephen R Wisniewski, Andrew A Nierenberg, Jonathan W Stewart, Diane Warden, George Niederehe, Michael E Thase, Philip W Lavori, Barry D Lebowitz,[...]. Am J Psychiatry 2006
23

Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression.
Duncan George, Verònica Gálvez, Donel Martin, Divya Kumar, John Leyden, Dusan Hadzi-Pavlovic, Simon Harper, Henry Brodaty, Paul Glue, Rohan Taylor,[...]. Am J Geriatr Psychiatry 2017
55
38

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.
Panos Zanos, Ruin Moaddel, Patrick J Morris, Lace M Riggs, Jaclyn N Highland, Polymnia Georgiou, Edna F R Pereira, Edson X Albuquerque, Craig J Thomas, Carlos A Zarate,[...]. Pharmacol Rev 2018
359
22

A randomized controlled trial of intranasal ketamine in major depressive disorder.
Kyle A B Lapidus, Cara F Levitch, Andrew M Perez, Jess W Brallier, Michael K Parides, Laili Soleimani, Adriana Feder, Dan V Iosifescu, Dennis S Charney, James W Murrough. Biol Psychiatry 2014
248
20

The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Samuel T Wilkinson, Elizabeth D Ballard, Michael H Bloch, Sanjay J Mathew, James W Murrough, Adriana Feder, Peter Sos, Gang Wang, Carlos A Zarate, Gerard Sanacora. Am J Psychiatry 2018
273
20

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Carlos A Zarate, Nancy E Brutsche, Lobna Ibrahim, Jose Franco-Chaves, Nancy Diazgranados, Anibal Cravchik, Jessica Selter, Craig A Marquardt, Victoria Liberty, David A Luckenbaugh. Biol Psychiatry 2012
496
18

Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Maurizio Fava, Marlene P Freeman, Martina Flynn, Heidi Judge, Bettina B Hoeppner, Cristina Cusin, Dawn F Ionescu, Sanjay J Mathew, Lee C Chang, Dan V Iosifescu,[...]. Mol Psychiatry 2020
123
18

Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).
Dawn F Ionescu, Dong-Jing Fu, Xin Qiu, Rosanne Lane, Pilar Lim, Siegfried Kasper, David Hough, Wayne C Drevets, Husseini Manji, Carla M Canuso. Int J Neuropsychopharmacol 2021
38
44

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Nancy Diazgranados, Lobna Ibrahim, Nancy E Brutsche, Andrew Newberg, Phillip Kronstein, Sami Khalife, William A Kammerer, Zenaide Quezado, David A Luckenbaugh, Giacomo Salvadore,[...]. Arch Gen Psychiatry 2010
648
17

Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
Jennifer L Phillips, Sandhaya Norris, Jeanne Talbot, Meagan Birmingham, Taylor Hatchard, Abigail Ortiz, Olabisi Owoeye, Lisa A Batten, Pierre Blier. Am J Psychiatry 2019
131
17

Mechanisms of ketamine action as an antidepressant.
P Zanos, T D Gould. Mol Psychiatry 2018
313
17

Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class.
Jean Kim, Tiffany Farchione, Andrew Potter, Qi Chen, Robert Temple. N Engl J Med 2019
99
16

Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
D Jeffrey Newport, Linda L Carpenter, William M McDonald, James B Potash, Mauricio Tohen, Charles B Nemeroff. Am J Psychiatry 2015
341
16

Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
James W Murrough, Andrew M Perez, Sarah Pillemer, Jessica Stern, Michael K Parides, Marije aan het Rot, Katherine A Collins, Sanjay J Mathew, Dennis S Charney, Dan V Iosifescu. Biol Psychiatry 2013
458
16

A Word to the Wise About Intranasal Esketamine.
Alan F Schatzberg. Am J Psychiatry 2019
51
27

Side-effects associated with ketamine use in depression: a systematic review.
Brooke Short, Joanna Fong, Veronica Galvez, William Shelker, Colleen K Loo. Lancet Psychiatry 2018
189
15

Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.
Nolan R Williams, Boris D Heifets, Christine Blasey, Keith Sudheimer, Jaspreet Pannu, Heather Pankow, Jessica Hawkins, Justin Birnbaum, David M Lyons, Carolyn I Rodriguez,[...]. Am J Psychiatry 2018
205
15

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
Panos Zanos, Ruin Moaddel, Patrick J Morris, Polymnia Georgiou, Jonathan Fischell, Greg I Elmer, Manickavasagom Alkondon, Peixiong Yuan, Heather J Pribut, Nagendra S Singh,[...]. Nature 2016
803
14

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.
Nanxin Li, Boyoung Lee, Rong-Jian Liu, Mounira Banasr, Jason M Dwyer, Masaaki Iwata, Xiao-Yuan Li, George Aghajanian, Ronald S Duman. Science 2010
14

Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Y-D Hu, Y-T Xiang, J-X Fang, S Zu, S Sha, H Shi, G S Ungvari, C U Correll, H F K Chiu, Y Xue,[...]. Psychol Med 2016
80
16

Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial.
Michael F Grunebaum, Hanga C Galfalvy, Tse-Hwei Choo, John G Keilp, Vivek K Moitra, Michelle S Parris, Julia E Marver, Ainsley K Burke, Matthew S Milak, M Elizabeth Sublette,[...]. Am J Psychiatry 2018
168
14


Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression.
C K Loo, V Gálvez, E O'Keefe, P B Mitchell, D Hadzi-Pavlovic, J Leyden, S Harper, A A Somogyi, R Lai, C S Weickert,[...]. Acta Psychiatr Scand 2016
103
14

Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study.
Fernanda S Correia-Melo, Gustavo C Leal, Flávia Vieira, Ana Paula Jesus-Nunes, Rodrigo P Mello, Guilherme Magnavita, Ana Teresa Caliman-Fontes, Mariana V F Echegaray, Igor D Bandeira, Samantha S Silva,[...]. J Affect Disord 2020
56
23

Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
Dong-Jing Fu, Dawn F Ionescu, Xiang Li, Rosanne Lane, Pilar Lim, Gerard Sanacora, David Hough, Husseini Manji, Wayne C Drevets, Carla M Canuso. J Clin Psychiatry 2020
49
26

A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.
Gerard Sanacora, Mark A Frye, William McDonald, Sanjay J Mathew, Mason S Turner, Alan F Schatzberg, Paul Summergrad, Charles B Nemeroff. JAMA Psychiatry 2017
246
13

Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
Dawn F Ionescu, Kate H Bentley, Matthias Eikermann, Norman Taylor, Oluwaseun Akeju, Michaela B Swee, Kara J Pavone, Samuel R Petrie, Christina Dording, David Mischoulon,[...]. J Affect Disord 2019
70
17




Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.
Ronald S Duman, George K Aghajanian, Gerard Sanacora, John H Krystal. Nat Med 2016
677
11

Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
J W Murrough, L Soleimani, K E DeWilde, K A Collins, K A Lapidus, B M Iacoviello, M Lener, M Kautz, J Kim, J B Stern,[...]. Psychol Med 2015
163
10

Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Le-Ben Wan, Cara F Levitch, Andrew M Perez, Jess W Brallier, Dan V Iosifescu, Lee C Chang, Alexandra Foulkes, Sanjay J Mathew, Dennis S Charney, James W Murrough. J Clin Psychiatry 2015
121
9

Esketamine for treatment resistant depression: a trick of smoke and mirrors?
C Gastaldon, D Papola, G Ostuzzi, C Barbui. Epidemiol Psychiatr Sci 2019
19
47


NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.
Anita E Autry, Megumi Adachi, Elena Nosyreva, Elisa S Na, Maarten F Los, Peng-fei Cheng, Ege T Kavalali, Lisa M Monteggia. Nature 2011
9

Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression.
Tung-Ping Su, Mu-Hong Chen, Cheng-Ta Li, Wei-Chen Lin, Chen-Jee Hong, Ralitza Gueorguieva, Pei-Chi Tu, Ya-Mei Bai, Chih-Ming Cheng, John H Krystal. Neuropsychopharmacology 2017
89
10

Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial.
Verònica Gálvez, Adrienne Li, Christina Huggins, Paul Glue, Donel Martin, Andrew A Somogyi, Angelo Alonzo, Anthony Rodgers, Philip B Mitchell, Colleen K Loo. J Psychopharmacol 2018
37
24

Intravenous arketamine for treatment-resistant depression: open-label pilot study.
Gustavo C Leal, Igor D Bandeira, Fernanda S Correia-Melo, Manuela Telles, Rodrigo P Mello, Flavia Vieira, Cassio S Lima, Ana Paula Jesus-Nunes, Lívia N F Guerreiro-Costa, Roberta F Marback,[...]. Eur Arch Psychiatry Clin Neurosci 2021
80
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.